期刊文献+

下呼吸道鲍曼不动杆菌感染的分布特点和耐药性及多重耐药菌的易感因素 被引量:26

下载PDF
导出
摘要 目的了解下呼吸道鲍曼不动杆菌(Ab)感染的临床分布特点和耐药性变迁,以及多重耐药菌感染的易感因素,为临床合理选用抗菌药物提供科学指导。方法回顾性分析384例下呼吸道感染患者的资料,并对痰标本分离出的384株Ab进行统计分析,同时在非多重耐药与多重耐药患者之间进行多重耐药易感因素分析。结果 2009、2010、2011年384例下呼吸道感染患者分离出Ab及其147株多重耐药菌株主要分布在呼吸内科,其次为重症监护病房(ICU)、神经内科及颅脑外科。2009、2010、2011年多重耐药Ab的构成比分别为35.58%、36.94%及41.96%。多重耐药菌株对多黏菌素B最敏感,其次为替加环素;对碳青霉烯类抗菌药物耐药率有逐年增加趋势;对含有β内酰胺酶抑制剂的复合抗菌药物包括哌拉西林/他唑巴坦、头孢哌酮/舒巴坦、氨苄西林/舒巴坦、头孢菌素、氟喹诺酮类、四环素类和磺胺类抗菌药物几乎全都耐药。Ab非多重耐药菌株对多黏菌素B、替加环素和碳青霉烯类抗菌药物最敏感;对阿米卡星、哌拉西林/他唑巴坦都较为敏感;对氟喹诺酮类抗菌药物耐药率约为20%。发生多重耐药菌感染与应用抗菌药物种类、合并慢性肺部疾病、心血管疾病、脑血管病、病情转归有关(P<0.05)。logistic逐步回归模型分析提示,应用抗菌药物种类、合并脑血管病、病情转归是发生多重耐药菌感染的独立影响因素。结论 Ab对多黏菌素B、替加环素较为敏感,对碳青霉烯类抗菌药物耐药率明显上升。患者应用抗菌药物种类、合并脑血管病、病情转归是发生多重耐药菌感染的独立影响因素。
出处 《广东医学》 CAS CSCD 北大核心 2012年第18期2812-2815,共4页 Guangdong Medical Journal
  • 相关文献

参考文献8

  • 1MARCHAIM D, NAVON VENEZIA S, SCHWART D, et al. Sur- veillance cultures and duration of carriage of multidrug - resistant Acinetobacter baum_annii [ J ]. J Clin Microbiol, 2001, 4-5 ( 5 ) : 1551 - 1555.
  • 2习慧明,徐英春,朱德妹,汪复,倪语星,孙景勇,孙自镛,简翠,胡云建,艾效曼,张泓,李万华,贾蓓,黄文祥,王传清,王爱敏,魏莲花,吴玲,卓超,苏丹虹,张朝霞,季萍,徐元宏,熊自忠,沈继录,单斌,杜艳,俞云松,杨青.2010年中国CHINET鲍曼不动杆菌耐药性监测[J].中国感染与化疗杂志,2012,12(2):98-104. 被引量:212
  • 3GORDON N C, WAREHAM D W. A review of clinical and micro- biological outcomes following treatment of infections involving mul- tidrug- resistant Acinetobacter baumannii with tigecycline [ J ]. J Antimicrob Chemother, 2009, 63(4) : 775 -780.
  • 4ADAMS HADUCH J M, PATERSON D L, SIDJABAT H E, et al. Genetic basis of muhidrug resistant in Aeinetobacter baumannii clinical isolates at a tertiary medical center in Pennsylvania [ J ]. Antimicrob Agents Chemother, 2008, 52 (11 ) : 3837 -3843.
  • 5LOLANS K, RICE T W, MUNOZ PRICE L S, et al. Multicity outbreak of carbapenem - resistant Acinetobacter baumannii iso-lates producing the carbapenemase OXA - 40 [ J ]. Antimicrob A- gents Chemother, 2006, 50(90) : 2941 -2945.
  • 6DU B, CHEN D, LIU D, et al. Restriction of third - generation cephalosporin use decreases infection-related mortalityl [ J]. Crit Care Med, 2003, 31(4) : 1088 -1093.
  • 7CHANDRA D, TSAI C L, CAMARGO C A Jr. Acute exacerba- tions of COPD : delay in presentation and the risk of hospitalization [J]. COPD, 2009, 6(2): 95-103.
  • 8MAGNASON S, KRISTINSSON K G, STEFANSSON T, et al. Risk factors and -outcome in ICU - acquired infections [ J ]. Acta Anaesthesiol Scand, 2008, 52(9) : 1238 -1245.

二级参考文献13

  • 1张小江,徐英春,俞云松,杨青,汪复,朱德妹,倪语星,孙景勇,孙自镛,简翠,胡云建,艾效曼,张泓,李万华,贾蓓,黄文祥,王传清,王爱敏,魏莲花,吴玲,卓超,苏丹虹,张朝霞,季萍,徐元宏,熊自忠,沈继录,单斌,杜艳.2009年中国CHINET鲍曼不动杆菌细菌耐药性监测[J].中国感染与化疗杂志,2010,10(6):441-446. 被引量:137
  • 2Clinical and Laboratory Standards Institute. Performancestandards for antimicrobial susceptibility testing~ twentieth information- al supplement[S]. CLSI, 2010,30 ( 1 ) : M100-S20.
  • 3Peleg AY, Seifert H, Paterson DL. Acinetobacterbauman- nil: emergence of a successful pathogen[J]. Clin Microbiol Rev,2008,21(3) :538-582.
  • 4Choi WS, Kim SH, Jeon EG, et al. Nosoeomial outbreak of carbapenem-resistant Acinetobacter baumannii in Intensive Care Units and successful outbreak control program[J]. J Korean Med Sci,2010, 25(7) :999-1004.
  • 5NNIS System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992through June 2003, issued August 2003 [J]. Am J Infect Control, 2003,31 (8) : 481 498.
  • 6Karageorgopoulous DE, Falagas ME. Current control and treatment of multidrug-resistant aclnetobacter baumannii in- fections[J]. Lancet Infect Dis, 2008,8 (12): 751-762.
  • 7Perez F, Hujer AM, Hujer KM, et al. Global Challenge of multidrug-resistant Acinetobacter baumannii [ J ]. Antimicrob Agents Chemother, 2007,51 (10) : 3471-3484.
  • 8Y Doi, Husain S, Potoski BA, et al. Extensively drug-resist- ant Acinetobacter baumannii [J ]. Emerg Infect Dis, 2009,15 (6):980-982.
  • 9Bassetti M, Righi E, Esposito S, et al. Drug treatment for multidrug-resistant Acinetobacter baumannii infections [J]. Future Microbiol, 2008,3 (6) .. 649-660.
  • 10Durante-Mangoni E, Zarrilli R. Global spread of drug-resist- ant Acinetobacter baumannii molecular epidemiology and management of antimicrobial resistance[J]. Future Microbi- ol,2011,6(4) :407-422.

共引文献211

同被引文献219

引证文献26

二级引证文献164

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部